Cargando…
Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach
BACKGROUND: High grade serous ovarian cancer is one of the poorly characterized malignancies. This study aimed to elucidate the mutational events in Malaysian patients with high grade serous ovarian cancer by performing targeted sequencing on 50 cancer hotspot genes. RESULTS: Nine high grade serous...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242548/ https://www.ncbi.nlm.nih.gov/pubmed/25404506 http://dx.doi.org/10.1186/1756-0500-7-805 |
_version_ | 1782345962811817984 |
---|---|
author | Ab Mutalib, Nurul-Syakima Syafruddin, Saiful Effendi Md Zain, Reena Rahayu Mohd Dali, Ahmad Zailani Hatta Mohd Yunos, Ryia Illani Saidin, Sazuita Jamal, Rahman Mokhtar, Norfilza M |
author_facet | Ab Mutalib, Nurul-Syakima Syafruddin, Saiful Effendi Md Zain, Reena Rahayu Mohd Dali, Ahmad Zailani Hatta Mohd Yunos, Ryia Illani Saidin, Sazuita Jamal, Rahman Mokhtar, Norfilza M |
author_sort | Ab Mutalib, Nurul-Syakima |
collection | PubMed |
description | BACKGROUND: High grade serous ovarian cancer is one of the poorly characterized malignancies. This study aimed to elucidate the mutational events in Malaysian patients with high grade serous ovarian cancer by performing targeted sequencing on 50 cancer hotspot genes. RESULTS: Nine high grade serous ovarian carcinoma samples and ten normal ovarian tissues were obtained from Universiti Kebangsaan Malaysia Medical Center (UKMMC) and the Kajang Hospital. The Ion AmpliSeq™ Cancer Hotspot Panel v2 targeting “mutation-hotspot region” in 50 most common cancer-associated genes was utilized. A total of 20 variants were identified in 12 genes. Eleven (55%) were silent alterations and nine (45%) were missense mutations. Six of the nine missense mutations were predicted to be deleterious while the other three have low or neutral protein impact. Eight genes were altered in both the tumor and normal groups (APC, EGFR, FGFR3, KDR, MET, PDGFRA, RET and SMO) while four genes (TP53, PIK3CA, STK11 and KIT) were exclusively altered in the tumor group. TP53 alterations were present in all the tumors but not in the normal group. Six deleterious mutations in TP53 (p.R175H, p.H193R, p.Y220C, p.Y163C, p.R282G and p.Y234H) were identified in eight serous ovarian carcinoma samples and none in the normal group. CONCLUSION: TP53 remains as the most frequently altered gene in high grade serous ovarian cancer and Ion Torrent Personal Genome Machine (PGM) in combination with Ion Ampliseq™ Cancer Hotspot Panel v2 were proven to be instrumental in identifying a wide range of genetic alterations simultaneously from a minute amount of DNA. However, larger series of validation targeting more genes are necessary in order to shed a light on the molecular events underlying pathogenesis of this cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1756-0500-7-805) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4242548 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42425482014-11-25 Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach Ab Mutalib, Nurul-Syakima Syafruddin, Saiful Effendi Md Zain, Reena Rahayu Mohd Dali, Ahmad Zailani Hatta Mohd Yunos, Ryia Illani Saidin, Sazuita Jamal, Rahman Mokhtar, Norfilza M BMC Res Notes Research Article BACKGROUND: High grade serous ovarian cancer is one of the poorly characterized malignancies. This study aimed to elucidate the mutational events in Malaysian patients with high grade serous ovarian cancer by performing targeted sequencing on 50 cancer hotspot genes. RESULTS: Nine high grade serous ovarian carcinoma samples and ten normal ovarian tissues were obtained from Universiti Kebangsaan Malaysia Medical Center (UKMMC) and the Kajang Hospital. The Ion AmpliSeq™ Cancer Hotspot Panel v2 targeting “mutation-hotspot region” in 50 most common cancer-associated genes was utilized. A total of 20 variants were identified in 12 genes. Eleven (55%) were silent alterations and nine (45%) were missense mutations. Six of the nine missense mutations were predicted to be deleterious while the other three have low or neutral protein impact. Eight genes were altered in both the tumor and normal groups (APC, EGFR, FGFR3, KDR, MET, PDGFRA, RET and SMO) while four genes (TP53, PIK3CA, STK11 and KIT) were exclusively altered in the tumor group. TP53 alterations were present in all the tumors but not in the normal group. Six deleterious mutations in TP53 (p.R175H, p.H193R, p.Y220C, p.Y163C, p.R282G and p.Y234H) were identified in eight serous ovarian carcinoma samples and none in the normal group. CONCLUSION: TP53 remains as the most frequently altered gene in high grade serous ovarian cancer and Ion Torrent Personal Genome Machine (PGM) in combination with Ion Ampliseq™ Cancer Hotspot Panel v2 were proven to be instrumental in identifying a wide range of genetic alterations simultaneously from a minute amount of DNA. However, larger series of validation targeting more genes are necessary in order to shed a light on the molecular events underlying pathogenesis of this cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1756-0500-7-805) contains supplementary material, which is available to authorized users. BioMed Central 2014-11-17 /pmc/articles/PMC4242548/ /pubmed/25404506 http://dx.doi.org/10.1186/1756-0500-7-805 Text en © Ab Mutalib et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Ab Mutalib, Nurul-Syakima Syafruddin, Saiful Effendi Md Zain, Reena Rahayu Mohd Dali, Ahmad Zailani Hatta Mohd Yunos, Ryia Illani Saidin, Sazuita Jamal, Rahman Mokhtar, Norfilza M Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach |
title | Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach |
title_full | Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach |
title_fullStr | Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach |
title_full_unstemmed | Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach |
title_short | Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach |
title_sort | molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242548/ https://www.ncbi.nlm.nih.gov/pubmed/25404506 http://dx.doi.org/10.1186/1756-0500-7-805 |
work_keys_str_mv | AT abmutalibnurulsyakima molecularcharacterizationofserousovariancarcinomausingamultigenenextgenerationsequencingcancerpanelapproach AT syafruddinsaifuleffendi molecularcharacterizationofserousovariancarcinomausingamultigenenextgenerationsequencingcancerpanelapproach AT mdzainreenarahayu molecularcharacterizationofserousovariancarcinomausingamultigenenextgenerationsequencingcancerpanelapproach AT mohddaliahmadzailanihatta molecularcharacterizationofserousovariancarcinomausingamultigenenextgenerationsequencingcancerpanelapproach AT mohdyunosryiaillani molecularcharacterizationofserousovariancarcinomausingamultigenenextgenerationsequencingcancerpanelapproach AT saidinsazuita molecularcharacterizationofserousovariancarcinomausingamultigenenextgenerationsequencingcancerpanelapproach AT jamalrahman molecularcharacterizationofserousovariancarcinomausingamultigenenextgenerationsequencingcancerpanelapproach AT mokhtarnorfilzam molecularcharacterizationofserousovariancarcinomausingamultigenenextgenerationsequencingcancerpanelapproach |